PDS Biotech Announces Interim Data
26/05/2023 09:39
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230526:nRSZ8160Aa&default-theme=true
RNS Number : 8160A NetScientific PLC 26 May 2023
Reach: For immediate release
NetScientific plc
("NetScientific" or the "Company")
PDS Biotech Announces Interim Data
Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with
KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
NetScientific Plc (AIM: NSCI), the investment and commercialisation group with
an international portfolio of innovative life science, sustainability and
technology companies, reports that its portfolio company, PDS Biotechnology
Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing
a growing pipeline of targeted immunotherapies for cancer and infectious
disease, has announced promising interim data.
The interim data relates to the VERSATILE-002 (NCT04260126) Phase 2 clinical
trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy,
KEYTRUDA® (pembrolizumab), in patients with unresectable, recurrent, or
metastatic human papillomavirus (HPV)16-positive head and neck cancer.
The results will be featured in a poster presentation and in a head and neck
cancer expert panel discussion at the 2023 American Society of Clinical
Oncology (ASCO) Annual Meeting being held from 2 - 6 June in Chicago.
The presentation, titled "Safety and Efficacy of Immune Checkpoint Inhibitor
(ICI) Naïve Cohort from Study of PDS0101 and Pembrolizumab in HPV16-positive
Head and Neck Squamous Cell Carcinoma (HNSCC)" (Abstract #6012), concluded
that the combination was well tolerated, and the results justify a global
confirmatory randomized, controlled study, VERSATILE-003, which PDS Biotech is
planning to initiate
(https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpdsbiotech.us4.list-manage.com%2ftrack%2fclick%3fu%3d407bd594246e0ad6fd93882af%26id%3dc1429d77f8%26e%3d27d88613f0&c=E,1,6LfSBjCdhCW3hYk903oWFBCDaNeA39wvJYSmagXHku2F8FijR-dxn9MPM7QxgZ8fNHhdNw0hY2neqoV47kKi648VM0eAMVDBw3eyhCOasiM0&typo=1)
this year
(https://linkprotect.cudasvc.com/url?a=https%3a%2f%2fpdsbiotech.us4.list-manage.com%2ftrack%2fclick%3fu%3d407bd594246e0ad6fd93882af%26id%3de9be8acd9e%26e%3d27d88613f0&c=E,1,XGYARINBJrtW6fGMyB66WCWUjSTSiQik2udN3gX7LWc8HpWckC0iObP7T_FO7dIio-LibkiiQECF681HMkZmchRbM4t2VcZnoRJmGuys42qbSQ,,&typo=1)
. The study's 48 ICI naïve participants, 94% of whom were male with a
median age of 62.5, received at least one cycle of the combination arm, 56.3%
received four doses, and 22.9% received five doses.
In measuring the efficacy of PDS0101 in combination with KEYTRUDA®, the
abstract highlights the following interim data:
· Estimated 12-month overall survival rate was 87.1%. Published results
are 36-50% with approved ICIs used alone*.
· Median progression-free survival was 10.4 months (95% CI 4.2, 15.3).
Published results are median PFS of 2-3 months for approved ICIs when used as
monotherapy in patients with similar PD-L1 levels*.
· A disease control rate (disease stabilization or tumor shrinkage)
of 70.6% (24/34).
· Confirmed and unconfirmed objective response rate was 41.2% (14/34
patients), which is identical to the preliminary response rate data PDS
Biotech previously reported at ASCO 2022 (7/17 patients). To date these
responses have been confirmed in nine of the 34 patients (26.5%), including
one complete response.
· 15/34 patients (44.1%) had stable disease.
· 9/34 patients (26.5%) had progressive disease.
· 4/48 (8.3%) of patients had a Grade 3 treatment-related adverse
event (TRAE). No Grade 4 or higher TRAEs were observed.
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and
safety of PDS0101 administered in combination with KEYTRUDA® in adults with
HPV16-positive unresectable, recurrent, or metastatic HNSCC. VERSATILE-002 is
investigating two patient populations of HPV16-positive head and neck cancer
patients whose cancer has returned or spread. Interim data from the first
group, which had not been previously treated with an ICI (ICI naïve), is the
focus of the ASCO poster presentation and follow-up discussion among a panel
of head and neck cancer experts. The second group of patients had previously
failed treatments including ICI therapy (ICI refractory).
Katharine A. Price, MD, Associate Professor, Oncology Head and Neck Disease
Group, Mayo Clinic and presenting author of the study said:
"We are pleased to present updated survival data from VERSATILE-002, which
suggest the addition of PDS0101 to KEYTRUDA® may improve survival for the
growing number of HPV16-positive head and neck cancer patients."
Lauren V. Wood, M.D., PDS Biotech's Chief Medical Officer and a co-author of
the study said:
"The interim data showed an estimated 12-month survival rate of 87% and a
progression-free survival of 10.4 months, which is very encouraging given the
poor prognosis these patients face. Furthermore, we remain encouraged by the
safety profile of PDS0101 in combination with KEYTRUDA®, with only 8% of
patients experiencing a Grade 3 treatment-related adverse event without more
serious Grade 4 or 5 events. We believe these data are encouraging for HNSCC
patients and indicate that the addition of the HPV16-targeted immunotherapy
PDS0101 to KEYTRUDA® should be further evaluated for its potential to enhance
survival in HPV16-positive head and neck cancer patients."
Dr Ilian Iliev, CEO of NetScientific, said:
"I am delighted with the interim data that will be presented by PDS at the
prestigious American Society of Clinical Oncology 2023 Annual Meeting,
demonstrating median progression-free survival of 10.4 months from the PDS
Phase 2 study focused on HPV16-positive head and neck cancer patients whose
cancer has returned or spread. PDS' programme continues to progress well
across its Phase 2 studies, and a planned Phase 3 programme. Congratulations
to Lauren and her team."
The research was authored by Katharine Price, M.D., Mayo Clinic; John Michael
Kaczmar, M.D., Medical University of South Carolina; Francis Worden, M.D.,
University of Michigan Health; Marya Chaney, Ph.D., Merck & Co. Inc.;
Jared Weiss, M.D., University of North Carolina, Chapel Hill; and PDS
Biotech's Lauren V. Wood, M.D; David Schaaf, M.D.; and Nathalie Riebel.
Details of the presentation are as follows:
Abstract Number: 6012
Abstract Title: Safety and Efficacy of Immune Checkpoint Inhibitor (ICI)
Naïve Cohort from Study of PDS0101 and Pembrolizumab in HPV16-Positive Head
and Neck Squamous Cell Carcinoma (HNSCC)
Presenting Author: Katharine Price, M.D., Co-chair, Head and Neck Disease
Group, Mayo Clinic Comprehensive Cancer Center
Session Title: Head and Neck Cancer
Poster Presentation: Monday, June 5, 2023, 1:15 PM-4:15 PM CDT
Head and Neck Cancer Poster Discussion Session: Monday, June 5, 2023, 4:30
PM-6:00 PM CDT
Conference call Information:
PDS Biotech will host a conference call on Tuesday, June 6, at 8:00 a.m. EDT
to discuss the interim data being presented at the ASCO 2023 Annual Meeting. A
live webcast of the event will be available online at PDS Biotech Post-ASCO
Webcast
(https://www.globenewswire.com/Tracker?data=ecX8kYcIjOpkiBMW5_FAIT_MwCtD0WOc4BID0UEHkRujVrHUxC8PY4B5TGQGKmmlFJUsU_E4yorkv_l36_-C_uFdjH8hjpf8u2Ucb4w3G8aaretkZtknOUCpYrglfNY-dpEXVjcw9zy6uCdrFJdXbQ==)
. The event will be archived in the investor relations section of PDS
Biotech's website for six months.
Additionally, interested participants and investors may access the conference
call by dialing either 877-407-3088 (US) or 201-389-0927 (International).
*No control or comparative studies have been conducted between immune
checkpoint inhibitors and PDS0101; Ferris R.L., Nivolumab for Recurrent
Squamous-Cell Carcinoma of the Head and Neck; N Engl J Med 2016;
375:1856-1867; Burtness B et al., Pembrolizumab alone or with chemotherapy
versus cetuximab with chemotherapy for recurrent or metastatic squamous cell
carcinoma of the head and neck (KEYNOTE- 048): a randomized, open-label phase
3 study; Lancet 2019; 394(10212):1915-1928
https://www.opdivo.com/head-and-neck-cancer
https://www.keytruda.com/head-and-neck-cancer/keytruda-clinical-trials/
A full version of PDS Biotech's announcement can be accessed here:
https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/838-iotechnnouncesnterimataemonstrates12onthu20230525
(https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/125-2023-news/838-iotechnnouncesnterimataemonstrates12onthu20230525)
-Ends-
For more information, please contact:
NetScientific
Ilian Iliev, CEO
Via Belvedere Communications
WH Ireland (NOMAD, Financial Adviser and Broker)
Chris Fielding / Darshan Patel / Enzo
Aliaj +44
(0)20 7220 1666
Belvedere Communications
John West / Llew
Angus
+44 (0) 203 008 6867
Email: nsci@belvederepr.com (mailto:nsci@belvederepr.com)
About NetScientific
NetScientific plc (AIM: NSCI) is an investment and commercialisation group
with an international portfolio of innovative life science, sustainability and
technology companies.
NetScientific identifies, invests in, and builds high growth companies in the
UK and internationally. The company adds value through the proactive
management of its portfolio, progressing to key value inflection points, and
delivering investment returns through partial or full liquidity events.
NetScientific differentiates itself by employing a capital-light investment
approach, making judicial use of its balance sheet and syndicating investments
through its wholly owned VC subsidiary, EMV Capital. The group secures a
mixture of direct equity stakes and carried interest stakes in its portfolio
of companies, creating a lean structure that can support a large portfolio.
NetScientific is headquartered in London, United Kingdom, and is admitted to
trading on AIM, a market operated by the London Stock Exchange.
www.netscientific.net (http://www.netscientific.net)
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing
pipeline of targeted cancer and infectious disease immunotherapies based on
our proprietary Versamune(®), Versamune(®) plus PDS0301, and Infectimune™
T cell-activating platforms. We believe our targeted immunotherapies have the
potential to overcome the limitations of current immunotherapy approaches
through the activation of the right type, quantity and potency of T cells. To
date, our lead Versamune(®) clinical candidate, PDS0101, has demonstrated
the ability to reduce and shrink tumours and stabilize disease in combination
with approved and investigational therapeutics in patients with a broad range
of HPV16-associated cancers in multiple Phase 2 clinical trials and will be
advancing into a Phase 3 clinical trial in combination with KEYTRUDA® for the
treatment of recurrent/metastatic HPV16-positive head and neck cancer in 2023.
Our Infectimune™ based vaccines have also demonstrated the potential to
induce not only robust and durable neutralizing antibody responses, but also
powerful T cell responses, including long-lasting memory T cell responses in
pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com
(https://www.globenewswire.com/Tracker?data=jRAUZ9vVihowpdAsEMPXLvawVyf6cWn4jSBNSs1Qxd4OH4pOFi1DwEgzyPG3jtm6swg3LuMFHyYXSSsbu8L9zLgSpPa8kdMkxXgrpy1QyLQ=)
or follow us on Twitter at @PDSBiotech.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUNOWROWUVURR